Research programme: cancer therapeutics - twoXAR

Alternative Names: TXR-311

Latest Information Update: 22 Mar 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator twoXAR
Developer Stanford University School of Medicine; twoXAR
Class Antineoplastics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Hepatocellular carcinoma

Most Recent Events

14 Mar 2017 Pharmacodynamics data from a preclinical study in Hepatocellular carcinoma released by twoXAR
13 Mar 2017 Preclinical trials in Hepatocellular carcinoma in USA before March 2017 (unspecified route)
08 Sep 2016 Early research in Hepatocellular carcinoma in USA (unspecified route)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.